Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Bridgers

Internal Medicine Irmo, SC Medical Doctor

NPI 1982696829 CMS profile 272015

7430 College St, Irmo, SC 29063

Open in the dashboard

General payments

$5,999

353 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Bridgers of Irmo, SC is reported in the CMS Open Payments database as having received $5,999 across 353 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $806 39
2024 General $712 38
2023 General $882 47
2022 General $1,060 58
2021 General $1,120 71
2020 General $694 48
2019 General $726 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Bridgers
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to David Bridgers were reported at $806. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year David Bridgers Internal Medicine median Middle half National median
2019 $726 $159 $48–$570 $163
2020 $694 $119 $33–$402 $114
2021 $1,120 $135 $37–$521 $132
2022 $1,060 $141 $42–$496 $149
2023 $882 $149 $45–$519 $160
2024 $712 $154 $47–$537 $164
2025 $806 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $737 47 payments
  2. Novo Nordisk Inc $543 34 payments
  3. AbbVie, Inc. $510 41 payments
  4. Amgen Inc. $411 24 payments
  5. Axsome Therapeutics, Inc. $300 12 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $289 19 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $253 14 payments
  8. Esperion Therapeutics, Inc. $224 13 payments
  9. Otsuka America Pharmaceutical, Inc. $223 11 payments
  10. Abbott Laboratories $196 11 payments
  11. Other $2,314 127 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,884 352 payments
  2. Long term medical supply or device loan $116 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $555 35 payments
  2. XIFAXAN $532 35 payments
  3. Ozempic $338 20 payments
  4. RYBELSUS $276 15 payments
  5. Sunosi $256 10 payments
  6. Kerendia $253 14 payments
  7. NEXLETOL $224 13 payments
  8. REXULTI $223 11 payments
  9. UBRELVY $187 14 payments
  10. ENTRESTO $174 11 payments
  11. Other $4,346 260 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 120 drugs

Part D claims

6,297

Median for Internal Medicine: 777

Drug cost

$698,176

Median for Internal Medicine: $73,373

Branded share of claims

20%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 115 $160,386
Mounjaro Tirzepatide Brand 100 $118,018
Eliquis Apixaban Brand 89 $110,706
Januvia Sitagliptin Phosphate Brand 34 $36,837
Farxiga Dapagliflozin Propanediol Brand 35 $33,667
Trulicity Dulaglutide Brand 26 $32,386
Jardiance Empagliflozin Brand 21 $31,681
Xarelto Rivaroxaban Brand 21 $19,112
Myrbetriq Mirabegron Brand 13 $16,079
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 28 $14,133

The 10 drugs with the highest cost, of 120 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$278,147

Of which drugs: $2,824

Medicare patients

464

Average age 76

Services billed

10,613

212 women, 252 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 39%
Ischemic heart disease 32%
Chronic kidney disease 21%
Cancer 20%
Atrial fibrillation 18%
Osteoporosis 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 31 31 $1,975
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 91 233 $208

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $83
$83 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $79
$79 35 —
ZEPOSIA
  • Celgene Corporation $64
$64 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $56
$56 — —
JARDIANCE
  • Lilly USA, LLC $39
  • Boehringer Ingelheim Pharmaceuticals, Inc. $14
$53 21 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

353 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record